Eternal Energy Corp.
http://www.eternalenergy.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Eternal Energy Corp.
Asia Deal Watch: SciClone Obtains Commercial Rights In China To Menarini Breast Cancer Drug
Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.
Shionogi Reveals Strategy For COVID-19 Drug Xocova
Shionogi is hoping to demonstrate the efficacy of its oral COVID-19 candidate Xocova through an appropriate primary endpoint in its Phase III trial, while the Japanese firm is also eyeing global expansion for the drug should a world-first domestic approval be granted.
Oncology R&D Boosts Korean Clinical Trials In 2015
With South Korean pharma firms and drug developers striving to turn into innovators, the number of clinical trials approved by regulatory authorities climbed last year, led by studies for cancer therapies, particularly those acting on the immune system, one of the most active research areas globally.
SymBio shifts bendamustine's multiple myeloma focus to second-line use
SymBio Pharmaceuticals has begun a Phase II trial in Japan with its lead product bendamustine for the treatment of the refractory and relapsed forms of multiple myeloma.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice